Followers | 3350 |
Posts | 86098 |
Boards Moderated | 5 |
Alias Born | 10/05/2005 |
Monday, March 12, 2018 11:31:31 PM
Date : 03/05/2018 @ 7:00AM
Source : PR Newswire (US)
Stock : Acelrx Pharmaceuticals, Inc. (ACRX)
Quote : 2.125 0.025 (1.19%) @ 8:00PM
AcelRx Pharmaceuticals to Participate at Three Upcoming Investor Events in March
Alert
Acelrx Pharmaceuticals, Inc. (NASDAQ:ACRX)
Historical Stock Chart
1 Month : From Feb 2018 to Mar 2018
Click Here for more Acelrx Pharmaceuticals, Inc. Charts.
REDWOOD CITY, Calif., March 5, 2018 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), (AcelRx), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain, today announced that that Vincent J. Angotti, Chief Executive Officer, will be presenting at the 30th Annual ROTH Conference, the 38th Annual Cowen Health Care Conference and the 28th Annual Oppenheimer Healthcare Conference. Details of the events are as follows:
30th Annual ROTH Conference
Date: Monday, March 12, 2018
Location: The Ritz-Carlton, Laguna Niguel
Presentation Time: 1:00 pm PT (4:00 pm ET)
38th Annual Cowen Health Care Conference
Date: Wednesday, March 14, 2018
Location: The Boston Marriott Copley Place, Boston
Presentation Time: 8:40 am ET (5:40 am PT)
28th Annual Oppenheimer Healthcare Conference
Date: Wednesday, March 21, 2018
Location: The Westin New York Grand Central, New York
Presentation Time: 11:30 am ET (8:30 am PT)
Presentations will be webcast live and can be accessed through the Investors page at www.acelrx.com. For those not available to listen to the live broadcast, a replay will be archived for 90 days and available through the Investors page on www.acelrx.com.
About AcelRx Pharmaceuticals, Inc.
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. AcelRx's proprietary, non-invasive sublingual formulation technology delivers sufentanil with consistent pharmacokinetic profiles. The company has two product candidates including DSUVIA™ (sufentanil sublingual tablet, 30 mcg), known as DZUVEO outside the United States, with a proposed indication for the treatment of moderate-to-severe acute pain in medically supervised settings, and ZALVISO® (sufentanil sublingual tablet system, SST system, 15 microgram) being developed as an innovatively designed patient-controlled analgesia (PCA) system for reduction of moderate-to-severe acute pain in medically supervised settings.
For additional information about AcelRx's clinical programs, please visit www.acelrx.com.
AcelRx logo. (PRNewsFoto/AcelRx Pharmaceuticals, Inc.)
Cision View original content with multimedia:http://www.prnewswire.com/news-releases/acelrx-pharmaceuticals-to-participate-at-three-upcoming-investor-events-in-march-300607717.html
SOURCE AcelRx Pharmaceuticals, Inc.
Copyright 2018 PR Newswire
Recent TLPH News
- Talphera to Participate in the H.C. Wainwright 26th Annual Global Investment Conference • PR Newswire (US) • 09/05/2024 08:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 09/03/2024 08:22:55 PM
- Talphera Announces First Patient Enrolled in the Registrational Trial Evaluating Nafamostat for Anticoagulation of the Extracorporeal Circuit • PR Newswire (US) • 08/19/2024 12:30:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/14/2024 09:22:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 08:12:36 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2024 08:10:32 PM
- Talphera Announces Second Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 08/14/2024 08:01:00 PM
- Talphera to Host Second Quarter 2024 Financial Results and Corporate Update Call and Webcast on Wednesday, August 14, 2024 • PR Newswire (US) • 08/05/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/14/2024 09:19:26 PM
- Talphera Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 05/20/2024 09:25:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 05/20/2024 09:22:15 PM
- Talphera to Participate at A.G.P. Virtual Healthcare Conference • PR Newswire (US) • 05/16/2024 09:45:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:00:59 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:15:28 PM
- Talphera Announces First Quarter 2024 Financial Results and Provides Corporate Update • PR Newswire (US) • 05/14/2024 08:05:00 PM
- Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024 • PR Newswire (US) • 05/02/2024 08:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/06/2024 10:00:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:11:29 PM
- Talphera Announces Fourth Quarter 2023 Financial Results and Provides Corporate Update • PR Newswire (US) • 03/06/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:55:33 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:54:23 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/05/2024 01:53:08 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 12:35:13 PM
- Talphera Announces Reduction in Size of its Board of Directors from Ten to Seven Members • PR Newswire (US) • 03/01/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/28/2024 02:06:44 AM
North Bay Resources Commences Operations at Bishop Gold Mill, Inyo County, California; Engages Sabean Group Management Consulting • NBRI • Sep 25, 2024 9:15 AM
CEO David B. Dorwart Anticipates a Bright Future at Good Gaming Inc. Through His Most Recent Shareholder Update • GMER • Sep 25, 2024 8:30 AM
Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • BLOZF • Sep 24, 2024 8:50 AM
Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • INTV • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM